✦ LIBER ✦

Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD

✍ Scribed by Eric Bateman; Gregory Feldman; Sally Kilbride; Jean Brooks; Rashmi Mehta; Stephanie Harris; Claire Maden; Glenn Crater

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of NVA237, a onc

✍ C. Vogelmeier; C. Verkindre; D. Cheung; J.B. Galdiz; S.Z. Güçlü; S. Spangenthal; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 457 KB

Sustained 24-h efficacy of NVA237, a onc

✍ C. Verkindre; Y. Fukuchi; A. Flémale; A. Takeda; T. Overend; N. Prasad; M. Dolke 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 447 KB

Bronchodilatory effects of NVA237, a onc

✍ Charles Fogarty; Helen Hattersley; Lilla Di Scala; Anton Drollmann 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 257 KB

A blinded evaluation of the efficacy and

✍ Chapman, Kenneth R; Beeh, Kai-Michael; Beier, Jutta; Bateman, Eric D; D’Urzo, An 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 225 KB

Safety and efficacy of the once-daily an

✍ Abrahams, Roger; Moroni-Zentgraf, Petra; Ramsdell, Joe; Schmidt, Hendrik; Joseph 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 550 KB

Long-term safety and efficacy of twice-d

✍ Gelb, Arthur F.; Tashkin, Donald P.; Make, Barry J.; Zhong, Xiaoyun; Garcia Gil, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 867 KB